Adsorbent for oral administration
An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m 2 /g or more, and a diffraction intensity ratio, an R value, determined by an equation (1): R =( I 15 −I 35 )/( I 24 −I 35 ) (1) wherein I 15 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 15°, I 35 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 35°, and I 24 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 24°, is 1.4 or more; and an adsorbent for an oral administration, characterized by comprising a surface-modified spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m 2 /g or more, a total amount of acidic groups is 0.40 to 1.00 meq/g, a total amount of basic groups is 0.40 to 1.10 meq/g, and a diffraction intensity ratio, an R value, determined by equation (1) is 1.4 or more. The adsorbents for oral administration exhibit a useful selective adsorbability, that is, a less adsorbability of useful substances in a body, and a greater adsorbability of toxic substances.
1. A pharmaceutical composition, comprising an adsorbent for oral administration and a pharmaceutically acceptable carrier or diluent, said adsorbent comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m 2 /g or more, and a diffraction intensity ratio, an R value, determined by an equation (1):
R =( I 15 −I 35 )/( I 24 −I 35 ) (1)
wherein I 15 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 15°, 1 35 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 35°, and I 24 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 24°, is 1.4 or more.
2. The pharmaceutical composition according to claim 1 , wherein a volume of pores having a diameter of 20 to 1000 nm is 1 mL/g or less.
3. The pharmaceutical composition according to claim 1 , wherein a volume of pores having a diameter of 7.5 to 15000 nm is less than 0.25 mL/g.
4. The pharmaceutical composition according to claim 1 , wherein the spherical activated carbon is prepared from the thermosetting resin, as a carbon source.
5. The pharmaceutical composition according to claim 1 , wherein the spherical activated carbon is prepared from the thermosetting resin having a carbonization yield of 40% by weight or more by a heat-treatment at 800° C. in an atmosphere of non-oxidative gas, as a carbon source.
6. A pharmaceutical composition, comprising an adsorbent for oral administration and a pharmaceutically acceptable carrier or diluent, said adsorbent comprising a surface-modified spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m 2 /g or more, a total amount of acidic groups is 0.40 to 1.00 meq/g, a total amount of basic groups is 0.40 to 1.10 meq/g, and a diffraction intensity ratio, an R value, determined by an equation (1):
R =( I 15 −I 35 )/( I 24 −I 35 ) (1)
wherein I 15 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 15°, I 35 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 35°, and I 24 is a diffraction intensity when a diffraction angle ( 2 θ) of an X-ray diffractometry is 24°, is 1.4 or more.
7. The pharmaceutical composition according to claim 6 , wherein a volume or pores having a diameter of 20 to 1000 nm is 1 mL/g or less.
8. The pharmaceutical composition according to claim 6 , wherein a volume of pores having a diameter of 7.5 to 15000 nm is less than 0.25 mL/g.
9. The pharmaceutical composition according to claim 6 , wherein the spherical activated carbon is prepared from a thermosetting resin, as a carbon source.
10. The pharmaceutical composition according to claim 6 , wherein the surface-modified spherical activated carbon is prepared from the thermosetting resin having a carbonization yield of 40% by weight or more by a heat-treatment at 800° C. in an atmosphere of non-oxidative gas, as a carbon source.
11. A method for treating or preventing a renal disease, comprising orally administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1 .
12. A method for treating or preventing a renal disease, comprising orally administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 6 .
13. A method for treating or preventing a liver disease, comprising orally administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 1 .
14. A method for treating or preventing a liver disease, comprising orally administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 6 .